CA2555848A1 — Antibody targeting osteoclast-associated protein
Assigned to Sankyo Co Ltd · Expires 2005-08-25 · 21y expired
What this patent protects
A method of detecting bone metabolic disorder by using a gene strongly expressed in osteoclasts; a method of screening a compound having an effect of treating and/or preventing bone metabolic disorder; and a medicinal composition for treating and/or preventing bone metabolic diso…
USPTO Abstract
A method of detecting bone metabolic disorder by using a gene strongly expressed in osteoclasts; a method of screening a compound having an effect of treating and/or preventing bone metabolic disorder; and a medicinal composition for treating and/or preventing bone metabolic disorder. Namely, a method of detecting bone metabolic disorder by using the expression of human DC-STAMP gene as an indication; a medicinal composition containing an antibody which specifically recognizes human DC-STAMP and has an activity of inhibiting the formation of osteoclasts, etc.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.